AC Immune’s (ACIU) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of AC Immune (NASDAQ:ACIU) in a report issued on Friday morning,Benzinga reports. They currently have a $16.00 price objective on the stock.

Separately, StockNews.com downgraded AC Immune from a “buy” rating to a “hold” rating in a research report on Tuesday, October 1st.

AC Immune Trading Down 1.7 %

Shares of NASDAQ:ACIU opened at $3.14 on Friday. The business has a 50-day moving average price of $3.28 and a 200 day moving average price of $3.49. The company has a market capitalization of $310.18 million, a price-to-earnings ratio of -7.07 and a beta of 1.28. AC Immune has a 12-month low of $2.25 and a 12-month high of $5.14.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC grew its holdings in AC Immune by 6.4% during the third quarter. Geode Capital Management LLC now owns 58,296 shares of the company’s stock worth $220,000 after acquiring an additional 3,499 shares during the period. Redmile Group LLC grew its holdings in AC Immune by 0.4% during the first quarter. Redmile Group LLC now owns 2,007,031 shares of the company’s stock worth $5,941,000 after acquiring an additional 7,031 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in AC Immune by 63.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 19,021 shares of the company’s stock worth $72,000 after acquiring an additional 7,400 shares during the period. BNP Paribas Financial Markets grew its holdings in AC Immune by 315.6% during the first quarter. BNP Paribas Financial Markets now owns 11,092 shares of the company’s stock worth $33,000 after acquiring an additional 8,423 shares during the period. Finally, Silverberg Bernstein Capital Management LLC acquired a new position in AC Immune during the second quarter worth $40,000. Institutional investors and hedge funds own 51.36% of the company’s stock.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.